开普拓治疗大肠癌的临床应用

Campto (CPT-11) treatment of advanced large intestinal cancer: clinical ex perience

目的 观察开普拓治疗晚期大肠癌的疗效及毒副反应。方法 将 2 3 7例大肠癌患者分为开普拓单药治疗组、开普拓 +DGM方案组和开普拓 +Mayo方案组 ,单药组开普拓剂量为 2 70mg/m2 ,联合化疗组开普拓剂量为 150mg/m2 。开普拓溶于 2 50ml生理盐水中 ,静脉滴注不少于 3 0min。结果全组可评价疗效者 186例 ,其中开普拓单药组的有效率为 2 7.9% ,开普拓 +DGM方案组为 3 2 .7% ,开普拓 +Mayo方案组为 2 7.3 %。在初治 55例患者中 ,开普拓单药组、开普拓 +DGM方案组和开普拓 +Mayo方案组的有效率分别为 3 3 .3 %、2 8.9%和 50 .0 % ;复治患者的有效率分别为 2 6.4%、3 4 .8%和2 2 .2 %。本组主要不良反应有胆碱能症状、迟发性腹泻和粒细胞减少 ,有 2例患者死亡。

Objective To evaluate the efficacy and toxicity of campto (CPT-11) monotherapy or combine d with 5Fu+leucovorin(CF) in advanced large intestinal cancer. Methods 186 such patients were divided into campto monotherapy group and CPT-11 plus 5Fu+CF[De Gramont (DGM) or Mayo protocal] groups. The mean dose of CPT-11 was 270 mg/m 2 alone in the monotherapy group and 150 mg/m 2 in the combination group. Campto was given as iv infusion in no less than 30-minutes . Results 186 patients were eligible for response evaluation. The response rates were 27.9 % in the monotherapy group, 32.7% in CPT-11+DGM and 27.3% in CPT-11+May o group. For 55 untreated patients,the response rates of monotherapy?Campto+ DGM and Campto+ Mayo regime groups were 33.3%?28.9% and 50.0%. For 131 treated pat ients, they were 26.4%?34.8% and 22.2%, respectively. The toxicities of the whole grou p were 16.0% cholinergic syndrome, 51.9% delayed diarrhea and 19.8% leuc openia. There were 2 treatment-related deaths. Conclusion The efficacy and toxicities of campto are similar as compared with the repo rts by other investigators.